We leveraged our 20 years of epigenomic expertise to help Universal Diagnostics (UDx) develop a customized early-detection workflow for colorectal cancer (CRC), integrating liquid biopsies with DNA methylation technologies for biomarker discovery and validation.
Capturing Biomarkers in Real-Time with Liquid Biopsy
Using cell-free DNA (cfDNA) isolated from plasma, biomarkers were monitored in realtime in the risk population.
DNA Methylation for Cancer Classification
Genome-wide methylation profiles from healthy and cancer patients were created to identify potential biomarkers.
Biomarker Validation
Once a pool of potential biomarkers was available, the best performers were identified.
“With the help of Hologic Diagenode’s experts, we are developing blood tests that detect cancer in its earliest stages.”
Kristi Kruusmaa
Chief Scientific Officer
Universal Diagnostics
